361 Capital LLC lifted its position in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) by 218.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 115,429 shares of the biotechnology company’s stock after purchasing an additional 79,161 shares during the period. 361 Capital LLC owned 0.10% of Corcept Therapeutics worth $2,228,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Suntrust Banks Inc. lifted its position in shares of Corcept Therapeutics by 4.0% during the second quarter. Suntrust Banks Inc. now owns 12,308 shares of the biotechnology company’s stock valued at $145,000 after purchasing an additional 471 shares in the last quarter. Strs Ohio raised its position in Corcept Therapeutics by 2.0% in the second quarter. Strs Ohio now owns 72,900 shares of the biotechnology company’s stock worth $860,000 after acquiring an additional 1,400 shares during the period. TIAA CREF Investment Management LLC raised its position in Corcept Therapeutics by 0.7% in the second quarter. TIAA CREF Investment Management LLC now owns 347,171 shares of the biotechnology company’s stock worth $4,097,000 after acquiring an additional 2,360 shares during the period. Metropolitan Life Insurance Co. NY raised its position in Corcept Therapeutics by 5.6% in the first quarter. Metropolitan Life Insurance Co. NY now owns 56,303 shares of the biotechnology company’s stock worth $617,000 after acquiring an additional 2,992 shares during the period. Finally, PNC Financial Services Group Inc. raised its position in Corcept Therapeutics by 52.6% in the second quarter. PNC Financial Services Group Inc. now owns 9,837 shares of the biotechnology company’s stock worth $116,000 after acquiring an additional 3,390 shares during the period. 63.59% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: “Corcept Therapeutics Incorporated (CORT) Position Lifted by 361 Capital LLC” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another website, it was copied illegally and republished in violation of international trademark and copyright laws. The legal version of this report can be read at https://www.thecerbatgem.com/2017/11/17/corcept-therapeutics-incorporated-cort-position-lifted-by-361-capital-llc.html.

In other news, Director G Leonard Baker, Jr. sold 30,000 shares of Corcept Therapeutics stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $17.59, for a total value of $527,700.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 19.20% of the stock is owned by company insiders.

Shares of Corcept Therapeutics Incorporated (NASDAQ CORT) traded up $0.60 during mid-day trading on Friday, reaching $19.05. 1,282,900 shares of the company’s stock traded hands, compared to its average volume of 1,092,658. The company has a market capitalization of $2,105.59, a price-to-earnings ratio of 63.62 and a beta of 2.04. Corcept Therapeutics Incorporated has a twelve month low of $6.70 and a twelve month high of $20.77.

Corcept Therapeutics (NASDAQ:CORT) last posted its earnings results on Thursday, November 2nd. The biotechnology company reported $0.11 earnings per share for the quarter, missing the consensus estimate of $0.13 by ($0.02). The business had revenue of $42.70 million during the quarter, compared to analysts’ expectations of $41.64 million. Corcept Therapeutics had a return on equity of 58.17% and a net margin of 27.28%. Corcept Therapeutics’s revenue for the quarter was up 96.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.02 EPS. analysts forecast that Corcept Therapeutics Incorporated will post 0.47 earnings per share for the current year.

Several analysts have commented on CORT shares. Stifel Nicolaus started coverage on shares of Corcept Therapeutics in a research report on Thursday, August 31st. They issued a “buy” rating and a $20.00 price objective on the stock. Zacks Investment Research lowered shares of Corcept Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, October 10th. Piper Jaffray Companies set a $18.00 price objective on shares of Corcept Therapeutics and gave the stock a “buy” rating in a research report on Thursday, August 24th. Finally, BidaskClub raised shares of Corcept Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, July 25th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. Corcept Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $18.20.

About Corcept Therapeutics

Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR).

Want to see what other hedge funds are holding CORT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Corcept Therapeutics Incorporated (NASDAQ:CORT).

Institutional Ownership by Quarter for Corcept Therapeutics (NASDAQ:CORT)

Receive News & Stock Ratings for Corcept Therapeutics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics Incorporated and related stocks with our FREE daily email newsletter.